LYEL logo

Lyell Immunopharma Inc. (LYEL)

$13.67

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on LYEL

Market cap

$437654824

EPS

-12.32

P/E ratio

--

Price to sales

7905.18

Dividend yield

--

Beta

-0.042668

Price on LYEL

Previous close

$14.65

Today's open

$14.58

Day's range

$13.26 - $14.75

52 week range

$7.20 - $45

Profile about LYEL

CEO

Lynn Seely

Employees

161

Headquarters

South San Francisco, CA

Exchange

Nasdaq Global Select

Shares outstanding

32015715

Issue type

Common Stock

LYEL industries and sectors

Healthcare

Biotechnology & Life Sciences

News on LYEL

Wall Street Analysts See a 148.25% Upside in Lyell Immunopharma (LYEL): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 148.3% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

news source

Zacks Investment Research • Nov 16, 2026

news preview

Lyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

Lyell Immunopharma, Inc. ( LYEL ) Stifel 2026 Healthcare Conference 2026 November 10, 2026 4:00 PM EST Company Participants Lynn Seely - Principal Executive Officer, President, CEO & Director Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Stephen Willey Stifel, Nicolaus & Company, Incorporated, Research Division I'm Stephen Willey, one of the Senior Biotech Analysts here at Stifel, and very glad to have with us from Lyell, CEO Lynn Seely. Lynn, thanks for joining us.

news source

Seeking Alpha • Nov 11, 2026

news preview

Lyell Immunopharma Targets Mid-2027 Pivotal Data for Lymphoma CAR-T Therapy

Lyell Immunopharma NASDAQ: LYEL expects pivotal data in mid-2027 for its lead CAR-T cell therapy, ronde-cel, as the company advances the treatment in patients with large B-cell lymphoma who have received at least two prior lines of therapy.

news source

MarketBeat • Nov 6, 2026

news preview

Lyell: Upgrade To 'Buy' On Ronde-Cel Advancement LBCL And $80 Million Funding Boost

Lyell Immunopharma is upgraded to “Buy” as pivotal ronde-cel CAR-T programs advance in relapsed/refractory large B-cell lymphoma [r/r LBCL]. LYEL secured $80 million in private placement, extending cash runway into 2028 and supporting ongoing pivotal and phase 3 trials. Key catalysts include ASH 2026 data updates for ronde-cel in 2nd/3rd-line r/r LBCL and phase 1/2 data for LYL273 in metastatic colorectal cancer.

news source

Seeking Alpha • Nov 5, 2026

news preview

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the third quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement of approximately $80 million of its common stock. The investors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund and other new and existing institutional investors.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients with 3L+ R/R LBCL in the PiNACLE pivotal trial Ronde-cel achieved a 95% overall response rate and 76% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 37 patients with 2L R/R LBCL in the Phase 1/2 trial No Grade ≥ 3 cytokine release syndrome was observed in either cohort and Grade ≥ 3 neurotoxicity was reported in < 10% of patients supporting outpatient administration SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that two abstracts featuring positive updated clinical data for rondecabtagene autoleucel (ronde-cel) have been accepted for presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans (ASH 2026).

news source

GlobeNewsWire • Nov 4, 2026

news preview

Lyell Immunopharma To Participate in November Investor Events

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the following investor events: Goldman Sachs' RxChange Series: Framing Lyell's next-generation lymphoma CAR-T data in 4Q Format: Fireside ChatFeatured Speaker: Alexander P.

news source

GlobeNewsWire • Nov 2, 2026

news preview

Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround

Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

news source

Zacks Investment Research • Oct 13, 2026

news preview

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026, in New York with a fireside chat scheduled for 2:00 pm Eastern Time.

news source

GlobeNewsWire • Sep 14, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Lyell Immunopharma Inc.

Open an M1 investment account to buy and sell Lyell Immunopharma Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in LYEL on M1